Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

IKT

Inhibikase Therapeutics Inc

Nov 21 • 04:00PM ET

1.49

-0.04 -2.61 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN JAZZ ALNY NBIX ARWR PTCT SUPN CLSD OCUL PBYI

| Held by: VTI IWM IWN VXF VTWO IWC IWO VTWV RSSL VTHR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.57	Insider Own	28.96%	Shs Outstand	74.81M	Perf Week	-2.61%
Market Cap	112.01M	Forward P/E	-	EPS next Y	-0.59	Insider Trans	0.00%	Shs Float	53.41M	Perf Month	-2.61%
Enterprise Value	34.69M	PEG	-	EPS next Q	-0.14	Inst Own	58.58%	Short Float	5.67%	Perf Quarter	-15.34%
Income	-47.66M	P/S	-	EPS this Y	54.74%	Inst Trans	0.59%	Short Ratio	18.44	Perf Half Y	-15.82%
Sales	0.00M	P/B	1.53	EPS next Y	-12.38%	ROA	-113.51%	Short Interest	3.03M	Perf YTD	-54.15%
Book/sh	0.97	P/C	1.45	EPS next 5Y	23.22%	ROE	-131.71%	52W High	4.20 -64.52%	Perf Year	-25.50%
Cash/sh	1.03	P/FCF	-	EPS past 3/5Y	38.01% 18.99%	ROIC	-65.37%	52W Low	1.33 12.03%	Perf 3Y	-59.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.70% 8.72%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	79.01%	Oper. Margin	-	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.67	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	44.33	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	11.67	EPS Q/Q	79.63%	SMA20	-3.72%	Beta	0.86	Target Price	8.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-5.62%	Rel Volume	27.46	Prev Close	1.53
Employees	16	LT Debt/Eq	0.00	Earnings	Nov 14 AMC	SMA200	-21.01%	Avg Volume	164.17K	Price	1.49
IPO	Dec 23, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	3,182,014	Change	-2.61%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-25	Downgrade	H.C. Wainwright	Buy → Neutral

Nov-20-25 09:54PM	Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:12PM	Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension (GlobeNewswire)
Nov-14-25 04:01PM	Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity (GlobeNewswire)
Aug-19-25 08:00AM	Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer (GlobeNewswire)
04:50PM	Loading…
Aug-14-25 04:50PM	Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity (GlobeNewswire)
May-14-25 04:05PM	Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity (GlobeNewswire)
May-02-25 05:07AM	Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH (Seeking Alpha)
Apr-14-25 08:00AM	Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer (GlobeNewswire)
Mar-27-25 04:01PM	Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity (GlobeNewswire)
Mar-05-25 09:55AM	Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Feb-24-25 08:00AM	Inhibikase Announces Expansion of Senior Leadership Team (GlobeNewswire) -16.50%
Feb-18-25 08:00AM	Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth (GlobeNewswire) +10.64%
Nov-14-24 08:37AM	Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity (GlobeNewswire)
Oct-23-24 06:31AM	Inhibikase Therapeutics Secures Funding and Strengthens Leadership (TipRanks) +15.17%
09:07PM	Loading…
Oct-22-24 09:07PM	Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc (GuruFocus.com)
Oct-21-24 09:05AM	Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension (GlobeNewswire)
Oct-18-24 01:01AM	Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc (GuruFocus.com) -9.36%
Oct-11-24 05:57PM	Inhibikase Therapeutics Secures $110M for Drug Development (TipRanks) +13.08% +8.16%
01:02PM	Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares (GuruFocus.com)
Oct-10-24 08:59AM	Inhibikase Therapeutics Unveils PAH and Parkinsons Drug Pipeline (TipRanks)
Oct-09-24 09:18AM	Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension (GlobeNewswire) +5.88%
Aug-14-24 04:25PM	Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity (GlobeNewswire) -5.80% -5.38%
Aug-07-24 08:00AM	Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 (GlobeNewswire)
Jun-17-24 08:05AM	Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease (GlobeNewswire) +12.77%
Jun-05-24 08:05AM	Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs (GlobeNewswire)
May-20-24 08:01AM	Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million (GlobeNewswire) +7.51%
May-19-24 08:09AM	Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-16-24 06:52AM	IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -11.56%
May-15-24 08:00PM	Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity (GlobeNewswire) +29.22%
08:45AM	Loading…
08:45AM	Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement (GlobeNewswire)
May-09-24 08:00AM	Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension (GlobeNewswire)
Apr-18-24 04:30PM	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs (GlobeNewswire)
Apr-03-24 08:05AM	Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension (GlobeNewswire)
Apr-02-24 10:25AM	Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 09:06PM	Q4 2023 Inhibikase Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.09%
Mar-27-24 10:53PM	IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
04:15PM	Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity (GlobeNewswire)
Mar-07-24 08:30AM	Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (GlobeNewswire)
Feb-28-24 04:05PM	Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro (GlobeNewswire)
Feb-15-24 09:55AM	Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now (Zacks) -6.69%
Feb-07-24 07:55AM	Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers (GlobeNewswire) -8.72%
Jan-29-24 09:05AM	Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib (GlobeNewswire) +8.45%
Jan-22-24 12:00PM	Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-16-24 04:05PM	Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli (GlobeNewswire) +10.69% -6.25%
Dec-19-23 08:30AM	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs (GlobeNewswire)
Dec-04-23 08:35AM	Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro (GlobeNewswire)
Nov-14-23 04:30PM	Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity (GlobeNewswire)
Nov-07-23 09:28AM	Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023 (GlobeNewswire)
08:00AM	Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023 (GlobeNewswire)
Oct-16-23 07:00AM	Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment (GlobeNewswire) +5.92%
Oct-04-23 08:30AM	Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy (GlobeNewswire) -26.43%
Sep-20-23 08:30AM	Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity (GlobeNewswire) +17.82%
Aug-24-23 08:30AM	Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib (PR Newswire)
Aug-22-23 08:05AM	Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire) -10.33%
Aug-21-23 08:30AM	Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib (PR Newswire)
Aug-17-23 08:30AM	Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro (PR Newswire)
Aug-15-23 11:47PM	Q2 2023 Inhibikase Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.02%
Aug-14-23 04:20PM	Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity (PR Newswire)
Aug-07-23 08:05AM	Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023 (PR Newswire)
Jul-17-23 04:05PM	Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements (PR Newswire)
Jun-29-23 09:29AM	Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split (PR Newswire)
Jun-22-23 08:05AM	Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study (PR Newswire) +9.64%
Jun-21-23 08:05AM	Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease (PR Newswire)
May-30-23 08:05AM	Inhibikase Therapeutics to Present at the LD Micro Invitational XIII (PR Newswire)
May-24-23 12:04PM	Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology (News Direct)
May-17-23 06:11AM	Inhibikase Therapeutics First Quarter 2023 Earnings: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022) (Simply Wall St.)
May-16-23 07:45AM	Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease (PR Newswire)
May-15-23 08:30AM	Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity (PR Newswire) +7.72%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-08-23 08:05AM	Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023 (PR Newswire)
May-04-23 08:05AM	Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference (PR Newswire) +6.62%
May-02-23 03:30PM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-26-23 08:00AM	Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease (PR Newswire) -7.90%
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -6.42%
Apr-21-23 08:30AM	Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase (PR Newswire)
Apr-07-23 10:25PM	Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 08:22AM	Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity (PR Newswire)
Mar-23-23 05:15PM	Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023 (PR Newswire) +8.66%
Mar-21-23 08:00AM	Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (PR Newswire)
Mar-16-23 08:30AM	Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023 (PR Newswire)
Mar-15-23 08:35AM	Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro (PR Newswire)
Mar-08-23 08:30AM	Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy (PR Newswire)
Feb-15-23 04:05PM	Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit (PR Newswire) +7.81%
Feb-08-23 01:00PM	Inhibikase Therapeutics raises $10M as disease treatments show success (American City Business Journals) +5.25%
Jan-27-23 04:05PM	Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules (PR Newswire) -7.32% +6.55%
Jan-25-23 01:00PM	Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules (PR Newswire) -5.49%
08:35AM	Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders (PR Newswire)
08:05AM	Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease (PR Newswire)
Dec-12-22 04:05PM	Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro (PR Newswire) +5.80%
Dec-07-22 04:05PM	Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs (PR Newswire) -7.41%
Nov-22-22 08:00AM	Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-14-22 05:45PM	Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity (PR Newswire) +8.52% +14.26%
Nov-10-22 05:00AM	The Petri Dish: Biogen's CEO search stalls again; A setback for Verve (American City Business Journals)
Nov-08-22 08:00AM	Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 (PR Newswire) +5.49%
Nov-07-22 08:00AM	Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs (PR Newswire) -40.91%
Oct-12-22 08:00AM	Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference (PR Newswire)
Sep-21-22 04:05PM	Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference (PR Newswire)
Sep-15-22 08:00AM	Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress (PR Newswire) +12.11%
Sep-13-22 12:15PM	Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation (Simply Wall St.)

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

IKT

Inhibikase Therapeutics Inc

Upgrade your FINVIZ experience